Skip to main content
. 2018 Dec 4;8:556. doi: 10.3389/fonc.2018.00556

Table 1.

Summary results of phase II and III studies evaluating the effect of rapalogs as a single agent in the treatment of refractory/relapsed NH B-cell lymphomas.

Disease Drug name Trial phase Nbe of patients in the cohort Dose administrated ORR (%) CR (%) DR (months) References Year of publication
MCL Temsirolimus II 35 250 mg weekly 38 3 6.9 (78) 2005
MCL Temsirolimus II 29 25 mg weekly 41 3.7 6 (79) 2008
MCL Temsirolimus III 162 175 mg weekly (for 3 weeks) followed by 75 or 25 mg weekly 22 (175/75 mg) 6 (175/25 mg) 2 (IC) 2 (175/75 mg) 0 (175/25 mg) 2 (IC) 7.1 (175/75 mg) 3.6 (175/25 mg) NA (IC) (80) 2009
MCL Everolimus II 19 10 mg daily 32 10.5 NA (81) 2011
MCL Everolimus II 35 10 mg daily 20 6 5.5 (82) 2012
DLBCL Temsirolimus II 32 25 mg 28 12.5 7.2 (83) 2010
DLBCL Everolimus II 47 10 mg daily 30 0 NA (81) 2011
FL Temsirolimus II 39 25 mg 54 25 12.5 (83) 2010
FL Everolimus II 8 10 mg daily 38 12.5 NA (81) 2011

ORR, overall response rate; CR, complete response; DR, duration response; MCL, Mantle Cell Lymphoma; DLBCL, Diffuse Large B Cell Lymphoma; FL, Follicular Lymphoma; IC, investigator's choice; NA, not available.